PharmGKB: The Pharmacogenomics Knowledge Base

Drug/Small Molecule:
rifampin

2D structure

Overview

Generic Names: RFP
Trade Names: Archidyn; L-5103 Lepetit; R/AMP; RAMP; Rfamipicin; Rifa; Rifadin; Rifadin IV; Rifadine; Rifagen; Rifaldazin; Rifaldazine; Rifaldin; Rifampicin; Rifampicin SV; Rifamycin; Rifamycin Amp; Rifaprodin; Rifoldin; Rifoldine; Riforal; Rimactan; Rimactane; Rimactin; Rimazid; Rofact; Tubocin
Brand Mixtures: Rifamate (Rifampin + Isoniazid); Rifater (Isoniazid + Pyrazinaamide + Rifampin)
PharmGKB Accession Id: PA451250

Description

A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160) (source: Drug Bank)

Indication

For the treatment of Tuberculosis and Tuberculosis-related mycobacterial infections. (source: Drug Bank)

ATC Therapeutic Category

  • J04AB:Antibiotics

Pharmacology, Interactions, and Contraindications

Mechanism Of Action

Rifampin acts via the inhibition of DNA-dependent RNA polymerase, leading to a suppression of RNA synthesis and cell death. (source: Drug Bank)

Pharmacology

Rifampin is an antibiotic that inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme. It is bactericidal and has a very broad spectrum of activity against most gram-positive and gram-negative organisms (including <i>Pseudomonas aeruginosa</i>) and specifically <i>Mycobacterium tuberculosis</i>. Because of rapid emergence of resistant bacteria, use is restricted to treatment of mycobacterial infections and a few other indications. Rifampin is well absorbed when taken orally and is distributed widely in body tissues and fluids, including the CSF. It is metabolized in the liver and eliminated in bile and, to a much lesser extent, in urine, but dose adjustments are unnecessary with renal insufficiency. (source: Drug Bank)

Food Interactions

Avoid alcohol.
Take on empty stomach: 1 hour before or 2 hours after meals.
Take with a full glass of water. (source: Drug Bank)

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

Primarily hepatic, rapidly deacetylated. (source: Drug Bank)

Protein Binding

89% (source: Drug Bank)

Absorption

Well absorbed from gastrointestinal tract. (source: Drug Bank)

Toxicity

LD<sub>50</sub>=1570 mg/kg (rat), chronic exposure may cause nausea and vomiting and unconsciousness (source: Drug Bank)

Isomeric SMILES Code:

Cc1c(c2c3c4c1O[C@@](C4=O)(OC=C[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]([C@H](C=CC=C(C(=O)Nc(c2O)c(c3O)C=NN5CCN(CC5)C)C)C)O)C)O)C)OC(=O)C)C)OC)C)O (source: Drug Bank)

Curated Annotations (Curated Annotation)

  1. rs2472677 at chr3:121001107 in NR1I2
    The CC homozygote of the NR1I2:63396C>T variant is associated with a high level of NR1I2 (PXR) gene induction by rifampicin as measured by increased activity of CYP3A4. This observation was particularly pronounced in livers from male subjects. Samples with the T allele had higher basal levels of NR1I2 mRNA and higher basal activity of CYP3A4. This SNP is predicted to be within a FOXA2 (HNF3beta) transcription factor binding site. This SNP is in LD with 63704G>A (rs12492296), 63813(CAAA)n/(CA)n, and 65104T>C.
    Variant Name:
    NR1I2:63396C>T, PXR 63396C>T
    Related Drugs:
    rifampin
    Evidence:
    PMID:17925385
  2. rs72551372 at chr3:121013162 in NR1I2
    cell based studies; enhanced basal activity of cyp3a4 transcription wrt WT
    Variant Name:
    V140M
    Related Drugs:
    rifampin
    Evidence:
    PMID:11602521
  3. rs72551374 at chr3:121013232 in NR1I2
    cell based studies; decreased basal activity on cyp3a4 transcription wrt WT; increased fold induction w/ rifampicin
    Variant Name:
    D163G
    Related Drugs:
    rifampin
    Evidence:
    PMID:11602521
  4. rs1045642 at chr7:86976581 in ABCB1
    ABCB1 rs2032582 and rs1045642 genotype and peripheral blood lymphocyte efflux of P-gp substrate, rhodamine 123 (Rh123), in vitro, in healthy males: there was no significant difference in Rh123 efflux in CD56+ NK cells after 5, 10, 15, and 30 min efflux, or in CD4+ T-helper cells after 15, 30, 60, and 90 min between individuals with different genotypes. Rh123 efflux was not enhanced by a 10-day administration of P-gp inducer, rifampin, in vivo in 15 individuals before and after rifampin treatment. No genotypic effect was observed for inhibition of Rh123 efflux by P-pg inhibitor, verapamil, in vitro with CD56+ and CD4+.
    Variant Name:
    ABCB1:3435C>T, mRNA 3853C>T, Ile1145Ile
    Related Drugs:
    rifampin, verapamil
    Evidence:
    PMID:12914549
  5. rs1045642 at chr7:86976581 in ABCB1
    Risk or phenotype-associated allele: none. Phenotype: No genetic association with dicloxacillin pharmacokinetics given 1g dicloxacillin prior to or after 600 mg rifampin (ABCB1 (P-gp) inducer). Study size: 18 (13 male). Study population/ethnicity: Healthy volunteers (12 Caucasian, 5 Asian, 1 African American, 1 subject undetermined) from San Francisco, California, USA. Significance metric(s): not significant. Type of association: GN; PK.
    Variant Name:
    ABCB1:3435T>C, Ile1145Ile
    Related Drugs:
    dicloxacillin, rifampin
    Evidence:
    PMID:15778422
  6. rs1045642 at chr7:86976581 in ABCB1
    Risk or phenotype-associated allele: none. Phenotype: No association with dicloxacillan pharmacokinetics given 1g dicloxacillan prior to or after 600 mg rifampin (ABCB1 (P-gp) inducer). Study size: 18 (13 male). Study population/ethnicity: Healthy volunteers (12 Caucasian, 5 Asian, 1 African American, 1 subject undetermined) from San Francisco, California, USA. Significance metric(s): not significant. Type of association: GN; PK.
    Variant Name:
    ABCB1:3435T>C, Ile1145Ile
    Related Drugs:
    dicloxacillin, rifampin
    Evidence:
    PMID:15778422
  7. rs2032582 at chr7:86998554 in ABCB1
    ABCB1 rs2032582 and rs1045642 genotype and peripheral blood lymphocyte efflux of P-gp substrate, rhodamine 123 (Rh123), in vitro, in healthy males: there was no significant difference in Rh123 efflux in CD56+ NK cells after 5, 10, 15, and 30 min efflux, or in CD4+ T-helper cells after 15, 30, 60, and 90 min between individuals with different genotypes. Rh123 efflux was not enhanced by a 10-day administration of P-gp inducer, rifampin, in vivo in 15 individuals before and after rifampin treatment. No genotypic effect was observed for inhibition of Rh123 efflux by P-pg inhibitor, verapamil, in vitro with CD56+ and CD4+.
    Variant Name:
    ABCB1:2677G>T/A, mRNA 3095G>T/A, Ala893Ser/Thr
    Related Drugs:
    rhodamine 123, rifampin, verapamil
    Evidence:
    PMID:12914549
Variant names are different names that have been used in the literature and other resources to refer to the same variant.

The following genes are in curated knowledge about this drug.

  Gene Relationship Evidence
Phenotype data available Genotype Data Available Literature annotations available Has annotations
ABCB1
  •   
  • PD
  • PK
  • FA
  • GN
Publications, Variants
Phenotype data available Genotype Data Available Literature annotations available Not annotated
ABCC2
  •   
  •   
  • PK
  •   
  • GN
Publications
No phenotype data Genotype Data Available Literature annotations available Not annotated
CYP1A2
  •   
  •   
  • PK
  • FA
  •   
Publications
No phenotype data Genotype Data Available Literature annotations available Not annotated
CYP24A1
  •   
  •   
  •   
  • FA
  •   
Publications
No phenotype data Genotype Data Available Literature annotations available Has annotations
CYP2A6
  •   
  •   
  •   
  • FA
  •   
Publications
Phenotype data available Genotype Data Available Literature annotations available Has annotations
CYP2B6
  • CO
  • PD
  • PK
  • FA
  • GN
Publications
Phenotype data available Genotype Data Available Literature annotations available Has annotations
CYP2C19
  •   
  •   
  • PK
  • FA
  •   
Publications
Phenotype data available Genotype Data Available Literature annotations available Not annotated
CYP2C8
  •   
  •   
  • PK
  • FA
  •   
Publications
Phenotype data available Genotype Data Available Literature annotations available Has annotations
CYP2C9
  •   
  •   
  • PK
  • FA
  •   
Publications
Phenotype data available Genotype Data Available Literature annotations available Has annotations
CYP2D6
  •   
  •   
  • PK
  •   
  •   
Publications
No phenotype data Genotype Data Available Literature annotations available Not annotated
CYP2E1
  •   
  •   
  •   
  • FA
  •   
Publications
Phenotype data available Genotype Data Available Literature annotations available Not annotated
CYP3A
  •   
  •   
  •   
  • FA
  •   
Publications
Phenotype data available Genotype Data Available Literature annotations available Has annotations
CYP3A4
  • CO
  • PD
  • PK
  • FA
  • GN
Publications
No phenotype data No genotype data Literature annotations available Has annotations
DRD2
  • CO
  • PD
  • PK
  •   
  • GN
Publications
Phenotype data available Genotype Data Available Literature annotations available Has annotations
NR1I2
  • CO
  • PD
  • PK
  • FA
  • GN
Publications, Variants
No phenotype data Genotype Data Available Literature annotations available Not annotated
NR1I3
  • CO
  • PD
  • PK
  •   
  • GN
Publications
No phenotype data Genotype Data Available Literature annotations available Has annotations
SLCO1B1
  •   
  •   
  • PK
  • FA
  • GN
Publications
No phenotype data Genotype Data Available Literature annotations available Not annotated
SLCO1B3
  •   
  •   
  • PK
  • FA
  •   
Publications
No phenotype data Genotype Data Available Literature annotations available Not annotated
SLCO2B1
  •   
  •   
  • PK
  • FA
  •   
Publications
Phenotype data available Genotype Data Available Literature annotations available Has annotations
UGT1A1
  • CO
  • PD
  • PK
  •   
  • GN
Publications

A list of non-curated publications that mention this drug along with other genes is available.

Drug Targets

Gene Description
ABCB1 Uncurated Annotation (source: Drug Bank)
NR1I2 Uncurated Annotation (source: Drug Bank)

PharmGKB Curated Pathways

The following drugs are in curated knowledge about this drug.

  Drug Relationship Evidence
No phenotype data No genotype data Literature annotations available Not annotated
atorvastatin
  •   
  •   
  •   
  •   
  •   
Publications
No phenotype data No genotype data Literature annotations available Not annotated
donepezil
  •   
  •   
  • PK
  •   
  •   
Publications
No phenotype data No genotype data Literature annotations available Not annotated
efavirenz
  •   
  •   
  •   
  •   
  •   
Publications
No phenotype data No genotype data Literature annotations available Not annotated
losartan
  •   
  •   
  • PK
  •   
  •   
Publications
No phenotype data No genotype data Literature annotations available Not annotated
nevirapine
  •   
  •   
  •   
  •   
  •   
Publications
No phenotype data No genotype data Literature annotations available Not annotated
risperidone
  •   
  •   
  • PK
  •   
  •   
Publications
No phenotype data No genotype data Literature annotations available Not annotated
sorafenib
  •   
  •   
  •   
  •   
  •   
Publications
Phenotype data available Genotype Data Available Literature annotations available Not annotated
warfarin
  •   
  •   
  •   
  •   
  •   
Publications

A list of non-curated publications that mention this drug along with other drugs is available.

Drug Interactions

Drug Description
acenocoumarol Uncurated Annotation The rifamycin decreases the anticoagulant effect (source: Drug Bank)
alfentanil Uncurated Annotation Rifampin reduces levels and efficacy of alfentanil (source: Drug Bank)
amiodarone Uncurated Annotation Rifampin decreases the effect of amiodarone (source: Drug Bank)
amitriptyline Uncurated Annotation The rifamycin decreases the effect of tricyclics (source: Drug Bank)
amoxapine Uncurated Annotation The rifamycin decreases the effect of tricyclics (source: Drug Bank)
amprenavir Uncurated Annotation In presence of rifampin, anticipate decrease of amprenavir (source: Drug Bank)
atazanavir Uncurated Annotation Rifampin reduces levels and efficacy of atazanavir (source: Drug Bank)
atorvastatin Uncurated Annotation The rifamycin decreases the effect of the statin drug (source: Drug Bank)
atovaquone Uncurated Annotation The agent decreases the effect of atovaquone (source: Drug Bank)
bisoprolol Uncurated Annotation Rifampin decreases the effect of the metabolized beta-blocker (source: Drug Bank)
bupropion Uncurated Annotation Rifampin reduces bupropion levels (source: Drug Bank)
buspirone Uncurated Annotation Rifampin decreases the effect of buspirone (source: Drug Bank)
celecoxib Uncurated Annotation Decreased levels/effect of the NSAID (source: Drug Bank)
cerivastatin Uncurated Annotation The rifamycin decreases the effect of the statin drug (source: Drug Bank)
chloramphenicol Uncurated Annotation Rifampin decreases the effect of chloramphenicol (source: Drug Bank)
chlorpropamide Uncurated Annotation Rifampin decreases the effect of sulfonylurea (source: Drug Bank)
clarithromycin Uncurated Annotation The rifamycin decreases the effect of the macrolide (source: Drug Bank)
clomipramine Uncurated Annotation The rifamycin decreases the effect of tricyclics (source: Drug Bank)
clozapine Uncurated Annotation Rifampin decreases the effect of clozapine (source: Drug Bank)
cortisone acetate Uncurated Annotation The enzyme inducer decreases the effect of the corticosteroid (source: Drug Bank)
cyclosporine Uncurated Annotation The rifamycin decreases the effect of cyclosporine (source: Drug Bank)
dapsone Uncurated Annotation Decreased levels of dapsone (source: Drug Bank)
dasatinib Uncurated Annotation Decreased levels/efficacy of dasatinib (source: Drug Bank)
delavirdine Uncurated Annotation Rifampin decreases the effect of delavirdine (source: Drug Bank)
desipramine Uncurated Annotation The rifamycin decreases the effect of tricyclics (source: Drug Bank)
dexamethasone Uncurated Annotation The enzyme inducer decreases the effect of the corticosteroid (source: Drug Bank)
diazepam Uncurated Annotation Rifampin decreases the effect of benzodiazepine (source: Drug Bank)
diclofenac Uncurated Annotation Decreased levels/effect of the NSAID (source: Drug Bank)
dicumarol Uncurated Annotation The rifamycin decreases the anticoagulant effect (source: Drug Bank)
diltiazem Uncurated Annotation Rifampin decreases levels of diltiazem (source: Drug Bank)
disopyramide Uncurated Annotation Rifampin decreases the effect of disopyramide (source: Drug Bank)
doxepin Uncurated Annotation The rifamycin decreases the effect of tricyclics (source: Drug Bank)
doxycycline Uncurated Annotation The rifamycin decreases the effect of doxycycline (source: Drug Bank)
enalapril Uncurated Annotation Rifampin decreases the effect of enalapril (source: Drug Bank)
erlotinib Uncurated Annotation Decreased levels/effect of erlotinib (source: Drug Bank)
erythromycin Uncurated Annotation The rifamycin decreases the effect of the macrolide (source: Drug Bank)
ethinyl estradiol Uncurated Annotation This product may cause a slight decrease of contraceptive effect (source: Drug Bank)
fentanyl Uncurated Annotation Rifampin reduces levels and efficacy of alfentanil (source: Drug Bank)
fluconazole Uncurated Annotation Fluconazole decreases the effect of imidazole (source: Drug Bank)
fluvastatin Uncurated Annotation The rifamycin decreases the effect of the statin drug (source: Drug Bank)
fosamprenavir Uncurated Annotation In presence of rifampin, anticipate decrease of amprenavir (source: Drug Bank)
gefitinib Uncurated Annotation Rifampin reduces levels and efficacy of gefitinib (source: Drug Bank)
glibenclamide Uncurated Annotation Rifampin decreases the effect of sulfonylurea (source: Drug Bank)
gliclazide Uncurated Annotation Rifampin decreases the effect of sulfonylurea (source: Drug Bank)
glimepiride Uncurated Annotation Rifampin decreases the effect of sulfonylurea (source: Drug Bank)
glipizide Uncurated Annotation Rifampin decreases the effect of sulfonylurea (source: Drug Bank)
haloperidol Uncurated Annotation The rifamycin decreases the effect of haloperidol (source: Drug Bank)
hydrocortisone Uncurated Annotation The enzyme inducer decreases the effect of the corticosteroid (source: Drug Bank)
imatinib Uncurated Annotation Rifampin decreases levels of imatinib (source: Drug Bank)
imipramine Uncurated Annotation The rifamycin decreases the effect of tricyclics (source: Drug Bank)
indinavir Uncurated Annotation Rifampin decreases the effect of indinavir (source: Drug Bank)
itraconazole Uncurated Annotation Rifampin decreases the effect of the imidazole (source: Drug Bank)
ketoconazole Uncurated Annotation Rifampin decreases the effect of the imidazole (source: Drug Bank)
lamotrigine Uncurated Annotation Rifampin decreases levels of lamotrigine (source: Drug Bank)
leflunomide Uncurated Annotation Rifampin increases the effect of leflunomide (source: Drug Bank)
losartan Uncurated Annotation Rifampin decreases the effect of losartan (source: Drug Bank)
lovastatin Uncurated Annotation The rifamycin decreases the effect of the statin drug (source: Drug Bank)
mefloquine Uncurated Annotation Rifampin lowers mefloquine levels (source: Drug Bank)
mephenytoin Uncurated Annotation Rifampin decreases the effect of the hydantoin (source: Drug Bank)
mestranol Uncurated Annotation This product may cause a slight decrease of contraceptive effect (source: Drug Bank)
methadone Uncurated Annotation The rifamycin decreases the effect of methadone (source: Drug Bank)
methylprednisolone Uncurated Annotation The enzyme inducer decreases the effect of the corticosteroid (source: Drug Bank)
metoprolol Uncurated Annotation Rifampin decreases the effect of the metabolized beta-blocker (source: Drug Bank)
mexiletine Uncurated Annotation Rifampin decreases the effect of mexiletine (source: Drug Bank)
midazolam Uncurated Annotation Rifampin decreases the effect of benzodiazepine (source: Drug Bank)
morphine Uncurated Annotation Rifampin decreases the effect of morphine/codeine (source: Drug Bank)
mycophenolate mofetil Uncurated Annotation Significant decrease in immunosuppressant levels (source: Drug Bank)
nelfinavir Uncurated Annotation Rifampin decreases the effect of nelfinavir (source: Drug Bank)
nifedipine Uncurated Annotation Rifampin decreases the effect of the calcium channel blocker (source: Drug Bank)
norethindrone Uncurated Annotation This product may cause a slight decrease of contraceptive effect (source: Drug Bank)
nortriptyline Uncurated Annotation The rifamycin decreases the effect of tricyclics (source: Drug Bank)
phenytoin Uncurated Annotation Rifampin decreases the effect of the hydantoin (source: Drug Bank)
prednisolone Uncurated Annotation The enzyme inducer decreases the effect of the corticosteroid (source: Drug Bank)
prednisone Uncurated Annotation The enzyme inducer decreases the effect of the corticosteroid (source: Drug Bank)
propafenone Uncurated Annotation Rifampin decreases the effect of propafenone (source: Drug Bank)
propranolol Uncurated Annotation Rifampin decreases the effect of the metabolized beta-blocker (source: Drug Bank)
protriptyline Uncurated Annotation The rifamycin decreases the effect of tricyclics (source: Drug Bank)
quinidine Uncurated Annotation Rifampin decreases the effect of quinidine (source: Drug Bank)
repaglinide Uncurated Annotation Rifampin decreases the effect of repaglinide (source: Drug Bank)
ritonavir Uncurated Annotation Rifampin decreases the effect of ritonavir (source: Drug Bank)
rofecoxib Uncurated Annotation Decreased levels/effect of the NSAID (source: Drug Bank)
rosiglitazone Uncurated Annotation Rifampin reduces levels and efficacy of rosiglitazone (source: Drug Bank)
saquinavir Uncurated Annotation Rifampin decreases the effect of saquinavir (source: Drug Bank)
simvastatin Uncurated Annotation The rifamycin decreases the effect of the statin drug (source: Drug Bank)
sirolimus Uncurated Annotation The rifamycin decreases the effect of sirolimus (source: Drug Bank)
sunitinib Uncurated Annotation Possible decrease in sunitinib levels (source: Drug Bank)
tacrolimus Uncurated Annotation The rifamycin decreases the effect of tacrolimus (source: Drug Bank)
tadalafil Uncurated Annotation Rifampin reduces levels and efficacy of tadalafil (source: Drug Bank)
tamoxifen Uncurated Annotation The rifamycin decreases the effect of anti-estrogen (source: Drug Bank)
telithromycin Uncurated Annotation Rifampin decreases the effect of telithromycin (source: Drug Bank)
terbinafine Uncurated Annotation Rifampin decreases the effect of terbinafine (source: Drug Bank)
theophylline Uncurated Annotation Rifampin decreases the effect of theophylline (source: Drug Bank)
tocainide Uncurated Annotation Rifampin lowers tocainide levels/effects (source: Drug Bank)
tolbutamide Uncurated Annotation Rifampin decreases the effect of sulfonylurea (source: Drug Bank)
toremifene Uncurated Annotation The rifamycin decreases the effect of anti-estrogen (source: Drug Bank)
triamcinolone Uncurated Annotation The enzyme inducer decreases the effect of the corticosteroid (source: Drug Bank)
triazolam Uncurated Annotation Rifampin decreases the effect of benzodiazepine (source: Drug Bank)
trimethoprim Uncurated Annotation Rifampin decreases the effect of trimethoprim (source: Drug Bank)
trimipramine Uncurated Annotation The rifamycin decreases the effect of tricyclics (source: Drug Bank)
verapamil Uncurated Annotation Rifampin decreases the effect of the calcium channel blocker (source: Drug Bank)
voriconazole Uncurated Annotation Rifampin decreases the effect of voriconazole (source: Drug Bank)
warfarin Uncurated Annotation The rifamycin decreases the anticoagulant effect (source: Drug Bank)
zaleplon Uncurated Annotation Rifampin decreases the effect of zaleplon (source: Drug Bank)
zidovudine Uncurated Annotation The rifamycin decreases levels of zidovudine (source: Drug Bank)

Curated Information

The following diseases are in curated knowledge about this drug.

  Disease Relationship Evidence
No phenotype data No genotype data Literature annotations available Not annotated
HIV
  • CO
  • PD
  • PK
  •   
  • GN
Publications
Phenotype data available Genotype Data Available Literature annotations available Not annotated
Leukemia
  • CO
  • PD
  • PK
  •   
  • GN
Publications
No phenotype data No genotype data Literature annotations available Not annotated
Meningitis, Bacterial
  • CO
  •   
  •   
  •   
  •   
Publications
No phenotype data No genotype data Literature annotations available Not annotated
Mycobacterium Infections
  •   
  •   
  • PK
  • FA
  •   
Publications
No phenotype data No genotype data Literature annotations available Not annotated
Osteomalacia
  •   
  •   
  •   
  • FA
  •   
Publications
No phenotype data No genotype data Literature annotations available Not annotated
Osteosarcoma
  •   
  •   
  •   
  • FA
  •   
Publications
No phenotype data No genotype data Literature annotations available Not annotated
Toxic liver disease
  •   
  • PD
  •   
  •   
  •   
Publications
No phenotype data No genotype data Literature annotations available Not annotated
Tuberculosis
  • CO
  • PD
  • PK
  •   
  •   
Publications

Non-Curated Information

A list of non-curated publications that mention this drug along with other diseases is available.

Curated Phenotype Datasets

These datasets are sorted alphabetically by title.

  1. In vivo and in vitro characterization of variants
    • Genotype data available
    • Phenotype data available
    • No literature annotations
    • Not annotated
    • PD
    • PK
    • FA
    Submitted by Mary Relling, PharmD involving CYP3A, CYP3A4, CYP3A5, NR1I2, , midazolam, nifedipine, rifampin and troleandomycin
  2. Testosterone 6beta-hydroxylation Activity Induced by Rifampin (Cohort I)
    • Genotype data available
    • Phenotype data available
    • No literature annotations
    • Not annotated
    • FA
    Submitted by Mary Relling, PharmD involving ABCB1, CYP3A4, and rifampin

Additional Datasets

These datasets are minimally curated and are sorted alphabetically by title.

  1. Genetic Variants in Isoniazid associated Hepatitis
  2. Physicochemical determinants of human renal clearance

Downloads

You must sign in before you can download data.

LinkOuts

Web Resource:
Wikipedia
DrugBank:
DB01045
ChEBI ID:
28077
KEGG Compound ID:
C06688
KEGG Drug ID:
D00211
PubChem Compound ID:
5381226
PubChem Substance ID:
168608

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Non-Curated Publications

A list of non-curated publications that mention this drug is available.

PharmGKB integrates drug information from different sources: DrugBank, Open Eye Scientific Software.
Add New Alternate Name
Add New ATC Term
Add Cross Reference
Add a metabolite
Add a text annotation
Add a drug target
hint: enter a gene
    Add a drug interaction
    hint: enter a drug
    PharmGKB® is a registered trademark of HHS and is financially supported by NIH/NIGMS. It is managed at Stanford University (GM61374).
    ©2001-2010 PharmGKB.